ncRNA basic information ncRNA ID: MIMAT0000076 ncRNA Database: miRBase ncRNA Name: miR-21-5p ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: RT-qPCR ncRNA Target Gene: PTEN and TIMP3 ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00997 (APRD00185, DB05331, DB05847) Drug Name: Doxorubicin Drug Method: The present study investigated the roles of microRNA (miR)-21-5p in the doxorubicin (DOX) resistance of GC cells and the underlying mechanisms. miR-21-5p expression levels were identified to be inversely correlated with two well-known tumor suppressor genes, phosphatase and tensin homologue and tissue inhibitor of matrix metalloproteinases 3, and were upregulated in GC cell lines in proportion to their degree of resistance. Suppressing miR-21-5p expression partially sensitized SGC7901/DOX cells to DOX, suggesting that knockdown of miR-21-5p expression may be used as a therapeutic strategy to improve GC cell resistance. Importantly, increased miR-21-5p expression levels at diagnosis were correlated with clinicopathological characteristics including advanced stage and poor prognosis, further implying that a relapse of GC may be a consequence of miR-21-5p upregulation, thus providing evidence for the potential utility of miR-21-5p antagonism to sensitize GC cells to DOX chemotherapy. Drug Response: sensitive

Cancer basic information Cancer: stomach cancer Tissue/Cell: cell line (SGC7901,HEK-293T,SGC7901/DOX,)

Other information Title: miR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Journal: Int J Mol Med Published: 2018 PubMed ID: 29393355